![]() ![]() The current funding will help us continue building our team, as well as supporting a robust sales and service effort for our customers,” added Feinstein. “This funding will help further develop SectionStar with the goal of launching in the non-clinical market in the very near future, and targeting the large clinical market as our ultimate goal. Clarapath’s SectionStar consolidates many manual cutting, quality control, and decision making steps into one piece of equipment, resulting in better quality tissue sections, faster processing efficiencies, and lower overall costs, all while providing richer data sets on those tissue specimens,” said Eric Feinstein, CEO of Clarapath, who was recently named one of the 40 under 40 Rising Stars by The Business Council of Westchester. “Being a manual process, AI-driven algorithms for interpretation of human tissues - particularly cancer - when examined on a cellular level are vulnerable to the variability in the quality of those tissue cross sections. The COVID-19 pandemic has exacerbated labor shortages, creating unacceptable delays in the delivery of timely biopsy results and driving up healthcare costs. Long overdue for a change, the current process is entirely manual, non-scalable, and is dependent on a shrinking workforce. This standardization in the quality of tissue sections is foundational for molecular mapping of human disease and in the development of new treatment pathways. The Company’s first robotic instrument, called SectionStar™, is a fully automated system which revolutionizes the reliability and efficiency of the pathology lab. Clarapath is automating processes around the way tissue is processed onto glass slides via “sectioning,” or cutting a cross-section of the tissue specimen.ĭelays in the lab fueled by COVID-19, labor shortages, and antiquated methods This brings the total raised by Clarapath to more than $39 million. The round included The 4100 Group, East Post Road Ventures (Investment Arm of White Plains Hospital), Epiphron Capital, Northwell Ventures, P5 Health Ventures, and participation from other strategic organizations. 18, 2021 (GLOBE NEWSWIRE) - Clarapath, a robotics company aimed at catalyzing change in the way pathology laboratories process human and animal tissues, today announced a follow-on financing, extending its Series B round with an additional $16 million in funding, following the previous close of $16 million in Series B funding. I hope the health service will continue to rise to the challenges we set them so that patients receive speedy treatment.HAWTHORNE, N.Y., Nov. "This is just another step forward in our drive to reduce long waits for patients in Wales. If the health service shows us what they can do successfully the money will be there to support them. "The NHS does face some tough challenges over the next year but this £32m is there to help the NHS meet that challenge. Where Trusts can make good use of the money their performance will be recognised but I want to make it clear that we will not accept performance which falls below the standards we require. I am determined to see this progress continued. These reductions are even more welcome today as they have been achieved during one of the most pressurised months in the history of the health service. "Figures published this morning show further falls in long waits over the last month. The aim will be to treat patients locally but if more capacity is required the Second Offer Scheme will secure treatment elsewhere. This money will be used to support Welsh Trusts and LHBs who feel they are able to treat more patients, quicker. "Today I am announcing an additional £32m for 2005/06 which will help the NHS in Wales meet the waiting times targets set for March 2006. But those targets are there to ensure that patients get the service they rightly expect. ![]() I am aware that pressure has also come from the Welsh Assembly Government as we continue to push Trusts to meet our waiting times targets. The funding will be made available in 2005/06 to help meet the targets that no patient will wait over 12 months for inpatient treatment or an outpatient appointment by March 2006.ĭr Gibbons said: "A&E departments across Wales have faced huge pressures over recent months which has put a strain on services throughout the NHS. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |